Guest guest Posted September 20, 2005 Report Share Posted September 20, 2005 Update from Novartis news release on AMN107 This excerpt was taken from a lengthy press release regarding Novartis's other drugs for Diabetes and cardiovascular health. Rather than post the entire article, I thought I'd just send the paragraph that regards CML... Cheers, Cheryl-Anne -- AMN107, a novel investigational oral compound being developed as a new treatment for advanced chronic myeloid leukemia (CML) patients, is planned to be submitted for regulatory approval in 2007. Enrollment in a pivotal Phase II study of patients with CML resistant to Gleevec/Glivec began in April 2005, with a Phase III study in chronic phase CML patients initiating treatment planned to begin in the first quarter of 2006. AMN107 further expands the Novartis franchise for helping patients with CML and GIST (gastrointestinal stromal tumors). Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.